Therapeutic Response

EGFR p.L858R status confers therapeutic sensitivity to Aumolertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Aumseqa (aumolertinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized aumolertinib as a monotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution variants.